Paradigm Therapeutics, Inc. Announces Investment by Eshelman Ventures, LLC to Support Completion of Development of SD-101 (Zorblisa™), A Topical Therapy for Treatment Across the Entire Skin Surface of All Subtypes of Epidermolysis Bullosa (EB)
Summary
First Topical Therapy Developed to Treat the Wounds and Lesions on the Entire Skin Surface Across All EB SubtypesFunding to be Used for Completion of All Activities to Support Planned NDA Submission in the Second Half of 2025, Along with Plans for Commercialization in the U.S.MT PLEASANT, S.C., May 6, 2025 /PRNewswire/ -- Paradigm Therapeutics, Inc., a biopharmaceutical company, announces a $12.5 Million investment by Eshelman Ventures, LLC and appointment of Dr. Eshelman as a strategic advisor for Paradigm. "We are excited about the opportunity to complete the development activities for SD-101 (Zorblisa) and to move a path forward towards registration of this therapy for patients with all EB subtypes," said Robert Ryan., Ph.D., Chief Executive Officer of Paradigm Therapeutics. The urgency of addressing the challenges faced by EB patients is what drives us; our goal is to provide an improved quality of life in this area of unmet need. SD-101 (Zorblisa) received Rare Pediatric Disease designation from the U.S. Food and Drug Administration (FDA) covering the broad treatment of EB. Upon approval, Paradigm will be eligible to receive a Priority Review Voucher (PRV).Paradigm Therapeutics, Inc. is a privately held, clinical-stage pharmaceutical company focused on developing innovative therapies to address critical medical needs in the treatment of rare diseases.